NASDAQ: KOOL BIO Investor Forum, San Francisco (Oct 22, 2019) Jeff Cauble, Vice President of Finance 1 | NASDAQ: KOOL 2 Disclosure and Forward Looking Statement This presentation includes statements of future expectations and other forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current views and assumptions, speak only as of the date hereof and are subject to change. Forward-loo ...

Cesca Therapeutics Inc. (KOOL) Q2 2019 Earnings Conference Call August 13, 2019 4:30 PM ET Company Participants Paula Schwartz - Managing Director, Rx Communications Chris Xu - Chairman & Chief Executive Officer Jeff Cauble - Principal Accounting Officer Conference Call Participants Sean Lee - HC Wainwright Operator Good day, and welcome to the Cesca Therapeutics Conference Call and Webcast to Review Financial and Operating Results for the Second Quarter ended June 30, 2019. As a reminder, all participants ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q X Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended June 30, 2019. or ___ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition from _____________ to _______________. Commission File Number: 000-16375 Cesca Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware ( ...

Cesca Therapeutics Inc. (NASDAQ:KOOL) Q1 2019 Earnings Conference Call May 14, 2019 4:30 PM ET Company Participants Paula Schwartz - Managing Director, Rx Communications Chris Xu - Chairman and Chief Executive Officer Jeff Cauble - Principal Accounting Officer Conference Call Participants Operator Good day, and welcome to the Cesca Therapeutics Conference Call and Webcast to Review Financial and Operating Results for the First Quarter Ended March 31, 2019. As a reminder, all participants will be in a listen ...

Table of Contents or ___ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition from _____________ to _______________. Commission File Number: 000-16375 Cesca Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware (State of incorporation) 94-3018487 SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q X Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended: December 31, 2018 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 ____________________________________ Commission File Number: 000-16375 Cesca Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware (State of incorporati ...

Cesca Therapeutics Inc. (KOOL) Q4 2018 Earnings Conference Call March 25, 2019 4:30 PM ET Company Participants Paula Schwartz - Managing Director, Rx Communications Chris Xu - Chairman and Chief Executive Officer Jeff Cauble - Principal Accounting Officer Conference Call Participants Swayampakula Ramakanth - H.C. Wainwright & Co. Operator Good day, and welcome to the Cesca Therapeutics Conference Call and Webcast to Review Financial and Operating Results for the Fiscal Year Ended December 31, 2018. As a rem ...